(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1663321

肝疾患治療薬 - 市場考察、競合情勢、市場予測（2032年）

Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
肝疾患治療薬 - 市場考察、競合情勢、市場予測（2032年）
出版日: 2025年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の肝疾患治療薬の市場規模は、2024年に200億2,075万米ドルであり、2032年までに301億1,363万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで5.32%の成長が見込まれます。世界の肝疾患治療薬需要は、主に肝臓関連疾患の有病率の上昇によって促進されています。主な要因としては、アルコール消費の増加、不健康な食生活、肝疾患とその管理に対する意識の高まりなどが挙げられます。早期診断、医療へのアクセス向上、肝疾患予防を目的とした公衆衛生への取り組みの高まりが、市場の拡大をさらに後押ししています。さらに、治療オプションの進歩と研究開発への投資の増加は、2025年～2032年の予測期間に肝疾患治療薬市場の成長を促進する見込みです。

肝疾患治療薬の市場力学

世界保健機関（WHO）の2024年の発表によると、2022年に約2億5,400万人がB型慢性肝炎に感染しており、毎年約120万人が新たに感染しています。さらに、PubMed Centralで公開された「世界の非アルコール性脂肪性肝疾患の罹患率と有病率」と題する近年の研究では、世界の非アルコール性脂肪性肝疾患（NAFLD）の罹患率は人口1,000人当たり47人と推定されています。同研究によると、成人のNAFLD有病率は32%で、女性（26%）に比べて男性（40%）の有病率が高いです。B型肝炎やC型肝炎、脂肪性肝疾患、肝硬変などの多くの肝疾患は長期的な管理が必要であるため、肝疾患患者の増加は治療需要の増加に直結します。

肝疾患治療薬市場の成長に寄与するもう1つの要因は、アルコールの消費と不適切な食生活の増加です。WHOの2024年のデータによると、約4億人（15歳以上の世界人口の7%）がアルコール使用障害を抱えており、そのうち2億900万人（成人人口の3.7%）がアルコール依存症に苦しんでいます。過度のアルコール摂取は肝細胞に脂肪を蓄積させ、アルコール関連肝疾患の初期段階である脂肪性肝疾患として知られる状態を引き起こす可能性があります。その結果、アルコール摂取の増加や食生活の乱れにより、肝疾患治療薬の需要は今後さらに高まると予測されます。

こうした成長促進要因にもかかわらず、肝疾患治療薬市場は、規制当局の厳しい承認プロセスや肝疾患治療薬に関連する潜在的な副作用などの課題に直面しており、このことが市場拡大の妨げとなる可能性があります。

北米が肝疾患治療薬市場全体を独占すると予測される

北米が2024年に肝疾患治療薬市場で最大のシェアを占めると予測されます。この優位性は主に、同地域における肝疾患の有病率の上昇、早期診断と疾患管理に対する患者の意識の高まり、強力な研究開発（R&D）活動、高いアルコール消費率、高齢化によってもたらされます。

米国疾病予防管理センター（CDC）の2023年のデータによると、米国では約88万人がB型慢性肝炎を患っています。肝炎などの肝疾患の負担の増加は、効果的な治療・管理ソリューションに対する需要を刺激し、市場成長を促進しています。

さらに、National Institute on Alcohol Abuse and Alcoholism（NIAAA）の2024年のレポートによると、米国の12歳以上の2億2,130万人（この年齢層の78.5%）が、人生のどこかでアルコールを摂取したことがあります。過度のアルコール摂取はさまざまな肝疾患の主な危険因子であり、肝疾患治療薬の必要性が高まっています。

北米の主要市場企業間の戦略的提携は、革新的な治療法の開発をさらに加速させています。例えば、Gilead Sciences, Inc.は2024年2月、CymaBay Therapeutics, Inc.を1株当たり現金32.50米ドルで買収する最終契約を締結し、Gileadの肝疾患治療薬のポートフォリオを拡大しました。

総合して、肝疾患の高い有病率、患者の意識の高まり、アルコール消費の増加、多額の研究開発投資、戦略的な産業提携などが、予測期間における北米の肝疾患治療薬市場の主な成長促進要因となっています。

当レポートでは、世界の肝疾患治療薬市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 肝疾患治療薬市場レポートのイントロダクション

第2章 肝疾患治療薬市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 肝疾患治療薬市場の主な要因の分析

  • 肝疾患治療薬市場の促進要因
  • 肝疾患治療薬市場の抑制要因と課題
  • 肝疾患治療薬市場の機会

第6章 肝疾患治療薬市場のポーターのファイブフォース分析

第7章 肝疾患治療薬市場の評価

  • 製品別
    • 抗ウイルス薬
    • コルチコステロイド
    • 免疫抑制剤
    • 化学療法薬
    • 免疫グロブリン
    • その他の製品
  • 疾患別
    • 肝炎
    • 自己免疫疾患
    • がん
    • 非アルコール性脂肪性肝疾患（NAFLD）
    • その他
  • エンドユーザー別
    • 病院薬局
    • 小売ドラッグストア
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 肝疾患治療薬市場の企業と製品のプロファイル

  • Abbott
  • Gilead Sciences
  • GSK plc.
  • F. Hoffmann-La Roche Ltd.
  • Astellas Pharma Inc.
  • Novartis AG
  • Madrigal Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceuticals
  • Amneal Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Alnylam Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Bayer AG
  • Viatris Inc.
  • Ipsen Pharma

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Liver Disease Therapeutics Market in Global (2022-2032)
  • Table 3: Liver Disease Therapeutics Market in Global by Product (2022-2032)
  • Table 4: Liver Disease Therapeutics Market in Global by Disease (2022-2032)
  • Table 5: Liver Disease Therapeutics Market in Global by End-User (2022-2032)
  • Table 6: Liver Disease Therapeutics Market in Global by Geography (2022-2032)
  • Table 7: Liver Disease Therapeutics Market in North America (2022-2032)
  • Table 8: Liver Disease Therapeutics Market in the United States (2022-2032)
  • Table 9: Liver Disease Therapeutics Market in Canada (2022-2032)
  • Table 10: Liver Disease Therapeutics Market in Mexico (2022-2032)
  • Table 11: Liver Disease Therapeutics Market in Europe (2022-2032)
  • Table 12: Liver Disease Therapeutics Market in France (2022-2032)
  • Table 13: Liver Disease Therapeutics Market in Germany (2022-2032)
  • Table 14: Liver Disease Therapeutics Market in United Kingdom (2022-2032)
  • Table 15: Liver Disease Therapeutics Market in Italy (2022-2032)
  • Table 16: Liver Disease Therapeutics Market in Spain (2022-2032)
  • Table 17: Liver Disease Therapeutics Market in the Rest of Europe (2022-2032)
  • Table 18: Liver Disease Therapeutics Market in Asia-Pacific (2022-2032)
  • Table 19: Liver Disease Therapeutics Market in China (2022-2032)
  • Table 20: Liver Disease Therapeutics Market in Japan (2022-2032)
  • Table 21: Liver Disease Therapeutics Market in India (2022-2032)
  • Table 22: Liver Disease Therapeutics Market in Australia (2022-2032)
  • Table 23: Liver Disease Therapeutics Market in South Korea (2022-2032)
  • Table 24: Liver Disease Therapeutics Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Liver Disease Therapeutics Market in the Rest of the World (2022-2032)
  • Table 26: Liver Disease Therapeutics Market in the Middle East (2022-2032)
  • Table 27: Liver Disease Therapeutics Market in Africa (2022-2032)
  • Table 28: Liver Disease Therapeutics Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Liver Disease Therapeutics Market in Global (2022-2032)
  • Figure 3: Liver Disease Therapeutics Market in Global by Product (2022-2032)
  • Figure 4: Liver Disease Therapeutics Market in Global by Disease (2022-2032)
  • Figure 5: Liver Disease Therapeutics Market in Global by End-User (2022-2032)
  • Figure 6: Liver Disease Therapeutics Market in Global by Geography (2022-2032)
  • Figure 7: Liver Disease Therapeutics Market in North America (2022-2032)
  • Figure 8: Liver Disease Therapeutics Market in the United States (2022-2032)
  • Figure 9: Liver Disease Therapeutics Market in Canada (2022-2032)
  • Figure 10: Liver Disease Therapeutics Market in Mexico (2022-2032)
  • Figure 11: Liver Disease Therapeutics Market in Europe (2022-2032)
  • Figure 12: Liver Disease Therapeutics Market in France (2022-2032)
  • Figure 13: Liver Disease Therapeutics Market in Germany (2022-2032)
  • Figure 14: Liver Disease Therapeutics Market in United Kingdom (2022-2032)
  • Figure 15: Liver Disease Therapeutics Market in Italy (2022-2032)
  • Figure 16: Liver Disease Therapeutics Market in Spain (2022-2032)
  • Figure 17: Liver Disease Therapeutics Market in the Rest of Europe (2022-2032)
  • Figure 18: Liver Disease Therapeutics Market in Asia-Pacific (2022-2032)
  • Figure 19: Liver Disease Therapeutics Market in China (2022-2032)
  • Figure 20: Liver Disease Therapeutics Market in Japan (2022-2032)
  • Figure 21: Liver Disease Therapeutics Market in India (2022-2032)
  • Figure 22: Liver Disease Therapeutics Market in Australia (2022-2032)
  • Figure 23: Liver Disease Therapeutics Market in South Korea (2022-2032)
  • Figure 24: Liver Disease Therapeutics Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Liver Disease Therapeutics Market in the Rest of the World (2022-2032)
  • Figure 26: Liver Disease Therapeutics Market in the Middle East (2022-2032)
  • Figure 27: Liver Disease Therapeutics Market in Africa (2022-2032)
  • Figure 28: Liver Disease Therapeutics Market in South America (2022-2032)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Marker Opportunities
  • Figure 32: PORTER'S Five Force Analysis
目次
Product Code: DISR0110

Liver Disease Therapeutics Market by Product (Antiviral Drugs, Corticosteroids, Immunosuppressants, Chemotherapy Drugs, Immunoglobulins, and Others), Disease (Hepatitis, Autoimmune Disorders, Cancer, Non-alcoholic Fatty Liver Disease, and Others), End-Users (Hospital Pharmacy, Retail Drug Stores, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of liver disease and increasing consumption of alcohol and improper diet.

The liver disease therapeutics market was valued at USD 20,020.75 million in 2024, growing at a CAGR of 5.32% during the forecast period from 2025 to 2032 to reach USD 30,113.63 million by 2032. The global demand for liver disease therapeutics is being driven primarily by the rising prevalence of liver-related conditions. Key contributing factors include increasing alcohol consumption, unhealthy dietary habits, and heightened awareness of liver diseases and their management. Growing efforts in early diagnosis, improved access to healthcare, and public health initiatives aimed at liver disease prevention are further supporting market expansion. Additionally, advancements in therapeutic options and increased investments in research and development are expected to propel the growth of the liver disease therapeutics market during the forecast period from 2025 to 2032.

Liver Disease Therapeutics Market Dynamics:

According to the World Health Organization (WHO) 2024, approximately 254 million people were living with chronic hepatitis B infection in 2022, with around 1.2 million new infections each year. Additionally, a recent study published in PubMed Central titled "Global incidence and prevalence of nonalcoholic fatty liver disease" estimated the global incidence of nonalcoholic fatty liver disease (NAFLD) at 47 cases per 1,000 population. The same study stated that the prevalence of NAFLD among adults is 32%, with a higher rate in males (40%) compared to females (26%). The growing number of patients with liver diseases directly translates to a higher demand for treatments, especially since many liver conditions, including hepatitis B and C, fatty liver disease, and cirrhosis, require long-term management.

Another factor contributing to the growth of the liver disease therapeutics market is the increasing consumption of alcohol and improper diet. According to the WHO 2024 data, approximately 400 million people (7% of the global population aged 15 years and older) live with alcohol use disorders, of which 209 million people (3.7% of the adult population) suffer from alcohol dependence. Excessive alcohol intake can lead to fat accumulation in liver cells, a condition known as fatty liver disease, which is the earliest stage of alcohol-related liver disease. Consequently, the rising prevalence of alcohol consumption and poor dietary habits is expected to further boost the demand for liver disease therapeutics in the coming years.

Despite these growth drivers, the liver disease therapeutics market faces challenges such as stringent regulatory approval processes and the potential side effects associated with liver disease therapies, which may hinder market expansion.

Liver Disease Therapeutics Market Segment Analysis:

Liver Disease Therapeutics Market by Product (Antiviral Drugs, Corticosteroids, Immunosuppressants, Chemotherapy Drugs, Immunoglobulins, and Others), Disease (Hepatitis, Autoimmune Disorders, Cancer, Non-alcoholic Fatty Liver Disease, and Others), End-Users (Hospital Pharmacy, Retail Drug Stores, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the liver disease therapeutics market, the chemotherapy drugs segment is projected to capture a substantial revenue share in 2024. According to Globocan 2022 data, approximately 866,136 individuals were diagnosed with liver cancer globally in 2022. This rising prevalence is a key factor driving the demand for chemotherapy drugs.

Chemotherapy remains a standard treatment option for liver cancer, particularly in advanced stages or when surgery is not feasible. Its effectiveness in shrinking tumors, slowing disease progression, and improving survival rates has made it a preferred therapeutic approach for various liver conditions.

Furthermore, ongoing investments in research and development have led to the introduction of more effective chemotherapy agents. Continuous innovation ensures that chemotherapy remains at the forefront of liver disease treatment. For example, in March 2023, Auransa Inc. partnered with the University of Southern California (USC) to initiate a Phase I clinical trial evaluating AU409, a novel therapy for liver cancers and solid tumors with liver-dominant disease.

Given these factors the increasing incidence of liver cancer, proven therapeutic efficacy, and advancements in drug development the chemotherapy drugs segment is expected to experience significant growth, thereby propelling the overall liver disease therapeutics market during the forecast period.

North America is expected to dominate the overall liver disease therapeutics market:

North America is projected to hold the largest share of the liver disease therapeutics market in 2024. This dominance is primarily driven by the rising prevalence of liver disorders in the region, increasing patient awareness of early diagnosis and disease management, robust research and development (R&D) initiatives, high alcohol consumption rates, and an aging population.

According to the Centers for Disease Control and Prevention (CDC) 2023 data, approximately 880,000 people in the United States live with chronic hepatitis B. The growing burden of liver diseases such as hepatitis is fueling demand for effective treatment and management solutions, thereby driving market growth.

Furthermore, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 2024 reported that 221.3 million individuals aged 12 and older in the U.S. (78.5% of this age group) have consumed alcohol at some point in their lives. Excessive alcohol consumption is a major risk factor for various liver conditions, increasing the need for liver disease therapeutics.

Strategic collaborations among key market players in North America are further accelerating the development of innovative treatments. For instance, in February 2024, Gilead Sciences, Inc. entered into a definitive agreement to acquire CymaBay Therapeutics, Inc. for USD 32.50 per share in cash, expanding Gilead's portfolio of liver disease therapeutics.

Collectively, the high prevalence of liver diseases, growing patient awareness, increasing alcohol consumption, significant R&D investments, and strategic industry collaborations are key factors propelling the growth of the liver disease therapeutics market in North America during the forecast period.

Liver Disease Therapeutics Market Key Players:

Some of the key market players operating in the liver disease therapeutics market include Abbott, Gilead Sciences, GSK plc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Madrigal Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, Amneal Pharmaceuticals, Inc., AbbVie Inc., Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Eli Lilly and Company, Exelixis, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Bayer AG, and Viatris Inc.

Recent Developmental Activities in the Liver Disease Therapeutics Market:

  • In June 2024, Ipsen's Iqirvo(R) received the U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis.
  • In March 2024, Madrigal Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Key Takeaways From The Liver Disease Therapeutics Market Report Study

  • Market size analysis for current liver disease therapeutics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the liver disease therapeutics market.
  • Various opportunities available for the other competitors in the liver disease therapeutics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current liver disease therapeutics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for liver disease therapeutics market growth in the coming future?

Target Audience Who Can Be Benefited From This Liver Disease Therapeutics Market Report Study

  • Liver disease therapeutics product providers
  • Research organizations and consulting companies
  • Liver disease therapeutics - related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in liver disease therapeutics
  • Various end-users who want to know more about the liver disease therapeutics market and the latest technological developments in the liver disease therapeutics market.

Frequently Asked Questions For The Liver Disease Therapeutics Market:

1. What is meant by liver disease therapeutics?

  • Liver disease therapeutics refer to the various treatments and interventions used to manage, treat, and potentially cure diseases and conditions affecting the liver. These therapeutics can include a wide range of approaches depending on the specific liver condition being addressed.

2. What is the market for liver disease therapeutics?

  • The liver disease therapeutics market was valued at USD 20,020.75 million in 2024, growing at a CAGR of 5.32% during the forecast period from 2025 to 2032 to reach USD 30,113.63 million by 2032.

3. What are the drivers for the global liver disease therapeutics market?

  • The liver disease therapeutics market is primarily being boosted by the increasing prevalence of liver diseases around the globe. Additionally, increasing consumption of alcohol and improper diet, and growing awareness regarding liver diseases are some of the key factors, which are contributing to the growth of the liver disease therapeutics market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global liver disease therapeutics market?

  • Some of the key market players operating in the liver disease therapeutics market include Abbott, Gilead Sciences, GSK plc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Novartis AG, Madrigal Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, Amneal Pharmaceuticals, Inc., AbbVie Inc., Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Eli Lilly and Company, Exelixis, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Bayer AG, and Viatris Inc.

5. Which region has the highest share in the global liver disease therapeutics market?

  • North America is expected to dominate the overall liver disease therapeutics market during the forecast period, 2025 to 2032. This is due to the growing prevalence of liver disorders in the region. Additionally, growing awareness among patients regarding the importance of early and accurate diagnosis and disease management of liver disorders, the presence of robust research and development initiatives, increasing prevalence of alcohol consumption, and the presence of an aging population are some of the key factors driving the growth of the liver disease therapeutics market in North America.

Table of Contents

1. Liver Disease Therapeutics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Liver Disease Therapeutics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Liver Disease Therapeutics Market Key Factors Analysis

  • 5.1. Liver Disease Therapeutics Market Drivers
    • 5.1.1. Rising prevalence of liver disease
    • 5.1.2. Increasing consumption of alcohol and improper diet
    • 5.1.3. Growing awareness regarding liver diseases
  • 5.2. Liver Disease Therapeutics Market Restraints and Challenges
    • 5.2.1. Stringent regulatory approval process
    • 5.2.2. Side effects associated with liver disease therapies
  • 5.3. Liver Disease Therapeutics Market Opportunities
    • 5.3.1. Increasing research and development for targeted therapies

6. Liver Disease Therapeutics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Liver Disease Therapeutics Market Assessment

  • 7.1. By Product
    • 7.1.1. Antiviral Drugs
    • 7.1.2. Corticosteroids
    • 7.1.3. Immunosuppressants
    • 7.1.4. Chemotherapy Drugs
    • 7.1.5. Immunoglobulins
    • 7.1.6. Other Products
  • 7.2. By Disease
    • 7.2.1. Hepatitis
    • 7.2.2. Autoimmune Disorders
    • 7.2.3. Cancer
    • 7.2.4. Non-alcoholic Fatty Liver Disease (NAFLD)
    • 7.2.5. Others
  • 7.3. By End-Users
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Drug Stores
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Liver disease Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Liver Disease Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.3. India Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Liver Disease Therapeutics Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Liver Disease Therapeutics Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Liver Disease Therapeutics Market Size in USD million (2022-2032)

8. Liver Disease Therapeutics Market Company and Product Profiles

  • 8.1. Abbott
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Gilead Sciences
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. GSK plc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. F. Hoffmann-La Roche Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Astellas Pharma Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Novartis AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Madrigal Pharmaceuticals
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Sanofi
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Takeda Pharmaceuticals
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Amneal Pharmaceuticals, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. AbbVie Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Alnylam Pharmaceuticals Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Merck & Co., Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Eli Lilly and Company
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Exelixis, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Bristol-Myers Squibb Company
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Eisai Co., Ltd.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Bayer AG
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Viatris Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Ipsen Pharma
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us